Novo Nordisk A/S (NYSE:NVO) – Analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for Novo Nordisk A/S in a research report issued on Thursday, March 14th. Jefferies Financial Group analyst P. Welford anticipates that the company will post earnings per share of $0.62 for the quarter. Jefferies Financial Group currently has a “Hold” rating on the stock. Jefferies Financial Group also issued estimates for Novo Nordisk A/S’s Q2 2019 earnings at $0.62 EPS, Q3 2019 earnings at $0.64 EPS, Q4 2019 earnings at $0.61 EPS, FY2019 earnings at $2.48 EPS, FY2020 earnings at $2.86 EPS, FY2021 earnings at $3.19 EPS and FY2023 earnings at $3.74 EPS.
Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Friday, February 1st. The company reported $0.54 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.57 by ($0.03). Novo Nordisk A/S had a net margin of 34.67% and a return on equity of 80.45%. The firm had revenue of $4.55 billion during the quarter, compared to analyst estimates of $4.36 billion.
Shares of NYSE:NVO opened at $50.89 on Friday. Novo Nordisk A/S has a 52-week low of $41.23 and a 52-week high of $51.64. The company has a market capitalization of $123.40 billion, a price-to-earnings ratio of 20.19, a PEG ratio of 2.33 and a beta of 0.59.
Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Novo Nordisk A/S by 8.3% in the fourth quarter. Geode Capital Management LLC now owns 39,942 shares of the company’s stock valued at $1,840,000 after buying an additional 3,060 shares during the last quarter. Princeton Global Asset Management LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at $55,000. Valley National Advisers Inc. lifted its stake in Novo Nordisk A/S by 1,012.4% in the fourth quarter. Valley National Advisers Inc. now owns 10,245 shares of the company’s stock valued at $472,000 after buying an additional 9,324 shares during the last quarter. Headinvest LLC lifted its stake in Novo Nordisk A/S by 94.4% in the fourth quarter. Headinvest LLC now owns 203,830 shares of the company’s stock valued at $9,390,000 after buying an additional 98,990 shares during the last quarter. Finally, Equitable Trust Co. lifted its stake in Novo Nordisk A/S by 11.6% in the fourth quarter. Equitable Trust Co. now owns 6,359 shares of the company’s stock valued at $293,000 after buying an additional 663 shares during the last quarter. 7.08% of the stock is owned by institutional investors and hedge funds.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.